02575oam 2200757 450 991070975890332120190204152659.0(CKB)5470000002472657(OCoLC)1042073861(EXLCZ)99547000000247265720180627d2018 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierAntitrust concerns and the FDA approval process hearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fifteenth Congress, first session, July 27, 2017Washington :U.S. Government Publishing Office,2018.1 online resource (iv, 51 pages)"Serial no. 115-27."Antitrust concerns and the FDA approval process DrugsUnited StatesTestingDrug approvalUnited StatesDrugsSafety regulationsUnited StatesMedical instruments and apparatusSafety regulationsUnited StatesGeneric drugsUnited StatesCompetitionUnited StatesAntitrust lawUnited StatesAntitrust lawfastCompetitionfastDrug approvalfastDrugsSafety regulationsfastDrugsTestingfastGeneric drugsfastMedical instruments and apparatusSafety regulationsfastUnited StatesfastLegislative hearings.fastRules.fastLegislative hearings.lcgftDrugsTesting.Drug approvalDrugsSafety regulationsMedical instruments and apparatusSafety regulationsGeneric drugsCompetitionAntitrust lawAntitrust law.Competition.Drug approval.DrugsSafety regulations.DrugsTesting.Generic drugs.Medical instruments and apparatusSafety regulations.GPOGPOGPOMERUCOCLCFINTOCLCQOCLCOGPOBOOK9910709758903321Antitrust concerns and the FDA approval process3518873UNINA